Last reviewed · How we verify
CHF5993 pMDI with HFA-134a
CHF5993 pMDI with HFA-134a is a Corticosteroid Small molecule drug developed by Chiesi Farmaceutici S.p.A.. It is currently in Phase 2 development for Maintenance treatment of asthma, Maintenance treatment of COPD.
CHF5993 pMDI with HFA-134a is a pressurized metered-dose inhaler formulation of a corticosteroid.
CHF5993 pMDI with HFA-134a is a pressurized metered-dose inhaler formulation of a corticosteroid. Used for Maintenance treatment of asthma, Maintenance treatment of COPD.
At a glance
| Generic name | CHF5993 pMDI with HFA-134a |
|---|---|
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
It is used for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The HFA-134a propellant is used to deliver the corticosteroid to the lungs.
Approved indications
- Maintenance treatment of asthma
- Maintenance treatment of COPD
Common side effects
- Oral thrush
- Headache
- Cough
Key clinical trials
- Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma (PHASE2)
- Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS). (PHASE3)
- Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR® (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHF5993 pMDI with HFA-134a CI brief — competitive landscape report
- CHF5993 pMDI with HFA-134a updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI
Frequently asked questions about CHF5993 pMDI with HFA-134a
What is CHF5993 pMDI with HFA-134a?
How does CHF5993 pMDI with HFA-134a work?
What is CHF5993 pMDI with HFA-134a used for?
Who makes CHF5993 pMDI with HFA-134a?
What drug class is CHF5993 pMDI with HFA-134a in?
What development phase is CHF5993 pMDI with HFA-134a in?
What are the side effects of CHF5993 pMDI with HFA-134a?
Related
- Drug class: All Corticosteroid drugs
- Manufacturer: Chiesi Farmaceutici S.p.A. — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Maintenance treatment of asthma
- Indication: Drugs for Maintenance treatment of COPD
- Compare: CHF5993 pMDI with HFA-134a vs similar drugs
- Pricing: CHF5993 pMDI with HFA-134a cost, discount & access